RASGRF2 and breast cancer: To accomplish this, we stained normal and breast disease tissues in a TMA that included non-malignant fibroadenomas and hyperplasia, malignant mostly carcinomas, inflammation, and metastatic breast cancer tissues with antibodies against AnxA6, GRF2, SOS1 and Ki67 (Fig 2A).